Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma

Digestive and Liver Disease

Volumn 43, Issue 4, 2011, Pages 333-334

  Diaz Sanchez, Antonio ^a   Rodriguez Salas, Nuria ^a   Aramendi, Teresa ^a   Balbin, Eva ^a  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; SORAFENIB;

ADULT; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN TISSUE; LEG PAIN; LETTER; LIVER CELL CARCINOMA; LIVER NODULE; MALE; MUSCLE BIOPSY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WALKING DIFFICULTY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MYOSITIS; PYRIDINES;

EID: 79952195430     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.11.009     Document Type: Letter

References (5)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
3. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
4. Joensuu H., Trent J., Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2010, 10.1016/j.ctrv.2010.04.008.
5. Hasinoff B.B., Patel D. Mechanism of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol 2010, 10:1-8.